http://www.cticseattle.com/investors.htm
Cell Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except for per share amounts)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
Revenues:
License and contract revenue $20 $20 $60 $60
Total revenues 20 20 60 60
Operating expenses:
Research and development 18,566 14,443 50,368 45,370
Selling, general and
administrative 8,874 9,057 24,594 27,819
Acquired in-process research
and development 21,343 - 21,343 -
Amortization of purchased
intangibles 219 200 638 588
Total operating expenses 49,002 23,700 96,943 73,777
Loss from operations (48,982) (23,680) (96,883) (73,717)
Other income (expense):
Investment and other income 626 607 2,067 1,843
Interest expense (2,463) (3,552) (10,057) (16,888)
Foreign exchange gain (loss) 2,308 (115) 3,142 997
Make-whole interest expense - (213) (2,310) (24,753)
Gain (loss) on derivative
liabilities 4 (879) 3,618 5,204
Gain on exchange of
convertible notes - -
'/>"/>
| SOURCE Cell Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved |